Cargando…

AML-355: Incidence and Severity of COVID-19 among Inpatients with Hematologic Malignancies

CONTEXT: COVID-19 has become the largest health crisis in recent history, with complex healthcare challenges in frontline and critical care settings or in assisting patients with chronic diseases and cancer. Hematologic malignancies (HM) represent an additional factor for severe COVID-19, and mortal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wozniaki, Natalia, Lacerda, Marcelo Pitombeira, Baptista, JoãoPedro Ribeiro, Cassi, Helio Vida, Neves, Gabriela Duarte, Boettcher, Ivan Schneider, Dall’Oglio, Ana Claudia, Tavares, Fabiana Sanchez, Gastal, Gabriela Roncone, Schwingel, Fabiano Luis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2021
Materias:	Acute Myeloid Leukemia
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404076/ http://dx.doi.org/10.1016/S2152-2650(21)01730-4

Ejemplares similares

Poster: AML-355: Incidence and Severity of COVID-19 among Inpatients with Hematologic Malignancies
por: Wozniaki, Natalia, et al.
Publicado: (2021)

AML-168: The Assessment of COVID-19 Evolution in Patients with Oncological Diseases Admitted in an Intensive Care Unit of One Romanian Center
por: Popov, Viola Maria, et al.
Publicado: (2021)

AML-075: Converting In-Person Research Procedures to a Virtual Platform During the COVID-19 Pandemic in Newly Diagnosed Acute Myeloid Leukemia Patients
por: Tinsley, Sara, et al.
Publicado: (2021)

AML-145: Outcomes of Induction Therapy in Patients with Acute Myeloid Leukemia During Covid-19 Pandemic: A Retrospective Study from a Tertiary Care Cancer Centre
por: Iqbal, Asif, et al.
Publicado: (2021)

Acute myeloid leukemia
por: Haferlach, Torsten
Publicado: (2019)

Clinical relevance of an objective flow cytometry approach based on limit of detection and limit of quantification for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial
por: Buccisano, Francesco, et al.
Publicado: (2022)

Early response evaluation in AML using mass cytometry
por: Gjertsen, Bjørn T., et al.
Publicado: (2019)

INCIDÊNCIA E GRAVIDADE DE COVID-19 ENTRE PACIENTES INTERNADOS PARA DIAGNÓSTICO E TRATAMENTO DE NEOPLASIAS HEMATOLÓGICAS
por: Baptista, JPR, et al.
Publicado: (2021)

Comprehensive molecular and clinical characterization of NUP98 fusions in pediatric acute myeloid leukemia
por: Bertrums, Eline J. M., et al.
Publicado: (2023)

Severity and 1-year cumulative incidence of COVID-19 among inpatients with haematologic malignancies
por: Ribeiro Baptista, J.P., et al.
Publicado: (2022)

AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill F LT 3-ITD acute myeloid leukemia
por: Post, Sean M., et al.
Publicado: (2021)

A risk score based on real-world data to predict early death in acute promyelocytic leukemia
por: Österroos, Albin, et al.
Publicado: (2022)

Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial
por: Russell, Nigel H., et al.
Publicado: (2021)

The retinoic acid receptor co-factor NRIP1 is uniquely upregulated and represents a therapeutic target in acute myeloid leukemia with chromosome 3q rearrangements
por: Grasedieck, Sarah, et al.
Publicado: (2021)

Acute myeloid leukemia: negative prognostic impact of early blast persistence can be in part overcome by a later remission prior to post-induction therapy
por: Ihlow, Jana, et al.
Publicado: (2021)

A novel CD34-specific T-cell engager efficiently depletes acute myeloid leukemia and leukemic stem cells in vitro and in vivo
por: Arruda, Lucas C. M., et al.
Publicado: (2022)

A self-assembled leucine polymer sensitizes leukemic stem cells to chemotherapy by inhibiting autophagy in acute myeloid leukemia
por: Xu, Xi, et al.
Publicado: (2022)

Clinical relevance of proteomic profiling in de novo pediatric acute myeloid leukemia: a Children’s Oncology Group study
por: Hoff, Fieke W., et al.
Publicado: (2022)

Meis1 supports leukemogenesis through stimulation of ribosomal biogenesis and Myc
por: Garcia-Cuellar, Maria-Paz, et al.
Publicado: (2022)

Pseudo-mutant P53 is a unique phenotype of DNMT3A-mutated pre-leukemia
por: Tuval, Amos, et al.
Publicado: (2022)

Persistent DNA damage and oncogenic stress-induced Trem1 promotes leukemia in mice
por: Li, Xue, et al.
Publicado: (2022)

Interplay between hypertriglyceridemia and acute promyelocytic leukemia mediated by the cooperation of peroxisome proliferator-activated receptor-α with the PML/RAR α fusion protein on super-enhancers
por: Wu, Shishuang, et al.
Publicado: (2022)

The NADPH oxidase NOX2 is a marker of adverse prognosis involved in chemoresistance of acute myeloid leukemias
por: Paolillo, Rosa, et al.
Publicado: (2022)

Improved outcomes with “7+3” induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data
por: Othus, Megan, et al.
Publicado: (2022)

Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4
por: Kayser, Sabine, et al.
Publicado: (2022)

Clinical and biological impact of ATP-binding cassette transporter activity in adult acute myeloid leukemia
por: Sourdeau, Elise, et al.
Publicado: (2022)

COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)
por: Marchesi, Francesco, et al.
Publicado: (2022)

Analysis of rare driving events in pediatric acute myeloid leukemia
por: Noort, Sanne, et al.
Publicado: (2022)

Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia
por: Orvain, Corentin, et al.
Publicado: (2022)

A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia
por: Pratz, Keith W., et al.
Publicado: (2022)

Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning
por: Eckardt, Jan-Niklas, et al.
Publicado: (2022)

Time spent at home among older adults with acute myeloid leukemia receiving azacitidine- or venetoclax-based regimens
por: Jensen, Christopher E., et al.
Publicado: (2022)

Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications
por: Nilsson, Christer, et al.
Publicado: (2022)

Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy
por: Zhang, Weiguo, et al.
Publicado: (2022)

Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy
por: Pabst, Thomas, et al.
Publicado: (2023)

Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia/myelodysplastic syndromes after a first transplantation
por: Yerushalmi, Yaara, et al.
Publicado: (2022)

Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia
por: Kuusanmäki, Heikki, et al.
Publicado: (2022)

Signal peptide-CUB-EGF-like repeat-containing protein 1-promoted FLT3 signaling is critical for the initiation and maintenance of MLL-rearranged acute leukemia
por: Sahoo, Binay K., et al.
Publicado: (2022)

Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells
por: Jia, Yannan, et al.
Publicado: (2023)

Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia
por: Gutman, Jonathan A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2d6es8nm992h8ubsksekucfs44